Structured Summary
Abstract
A polyethylene-glycolated Fab' fragment of TUMOR NECROSIS FACTOR antibody that binds specifically to TNF-ALPHA and neutralises it in a dose-dependent manner. It also inhibits the production of lipopolysaccharide-induced TNF-ALPHA and IL-1 BETA and is used to treat RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
MeSH Record
Classification
Related Concepts
Knowledge Graph
Drag nodes to rearrange; hover to trace links; click a node to open its page.
Drug Class
Pharmacological Action
MeSH Record
See Also
MeSH Record
Synonyms
3 entry terms
- CDP 870
- CDP870
- Cimzia
MeSH Record
Aspects Covered
24 allowable subheadings
Indexed with the subheadings administration & dosage, adverse effects, analysis, biosynthesis, blood, cerebrospinal fluid, chemistry, classification, drug effects, economics, genetics, history, immunology, isolation & purification, metabolism, pharmacokinetics, pharmacology, physiology, poisoning, radiation effects, therapeutic use, toxicity, ultrastructure, urine.
MeSH Record
History Note
2016 (2003)
MeSH Hierarchy
Tree Numbers
AMA Style
References
- National Library of Medicine. Certolizumab Pegol. Medical Subject Headings (MeSH). 2026. Unique ID D000068582. http://id.nlm.nih.gov/mesh/2026/D000068582
- Certolizumab Pegol. In: Wikipedia. https://en.wikipedia.org/wiki/Certolizumab_pegol
- Certolizumab Pegol. In: Wikidata. https://www.wikidata.org/wiki/Q412909